Top

Open Access 10-05-2024 | Stress Incontinence | Review

Pharmacotherapy in Stress Urinary Incontinence; A Literature Review

Authors: Seyed Sajjad Tabei, Wesley Baas, Ayman Mahdy

Abstract

Purpose of Review

Stress urinary incontinence (SUI) is a commonly observed condition in females, as well as in males who have undergone prostatectomy. Despite the significant progress made in surgical techniques, pharmacotherapy has not yielded substantial outcomes within the clinical domain. This review aims to present a comprehensive overview of the existing pharmacotherapy options for stress urinary incontinence (SUI) and the emerging therapeutic targets in this field.

Recent Findings

One meta-analysis demonstrated that α-adrenergic medications are more efficacious in improving rather than curing SUI symptoms. One trial showed reduced pad weight gain with PSD-503, a locally administered α-adrenergic receptor agonist. New data show that duloxetine’s risk outweighs its benefits. One small-scale trial was found to support the use of locally administered estriol in improving subjective outcomes. Emerging targets include serotonin 5HT_2C agonists, selective inhibitors of norepinephrine uptake, and myostatin inhibitors.

Summary

Only one of the evaluated drugs, duloxetine, has been approved by some countries. Currently, trials are evaluating novel targets. Systemic adverse effects such as gastrointestinal upset with duloxetine and orthostatic hypotension with α-adrenoceptor agonists have hampered the efficacy of drugs used to treat SUI in women and men.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. https://doi.org/10.1002/nau.10052.CrossRefPubMed

Luber KM. The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol. 2004;6(Suppl 3):S3-9.PubMedPubMedCentral

Baessler K, Christmann-Schmid C, Maher C, Haya N, Crawford TJ, Brown J. Surgery for women with pelvic organ prolapse with or without stress urinary incontinence. Cochrane Database Syst Rev. 2018;8(8):Cd013108. https://doi.org/10.1002/14651858.Cd013108.CrossRefPubMed

Lee UJ, Feinstein L, Ward JB, Kirkali Z, Martinez-Miller EE, Matlaga BR, et al. Prevalence of urinary incontinence among a nationally Representative Sample of women, 2005–2016: findings from the urologic diseases in America Project. J Urol. 2021;205(6):1718–24. https://doi.org/10.1097/JU.0000000000001634.CrossRefPubMed

Chong EC, Khan AA, Anger JT. The financial burden of stress urinary incontinence among women in the United States. Curr Urol Rep. 2011;12(5):358–62. https://doi.org/10.1007/s11934-011-0209-x.CrossRefPubMed

Hampson LA, Shaw NM, Breyer BN, Walter LC, Sudore RL, Cooperberg MR, et al. Patient-identified treatment attributes among older men with stress urinary incontinence: a qualitative look at what matters to patients making treatment decisions. Urology. 2023;177:189–96. https://doi.org/10.1016/j.urology.2022.12.071.CrossRefPubMed

Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88-119. https://doi.org/10.1038/sj.bjp.0706619.CrossRefPubMedPubMedCentral

Michel MC, Cardozo L, Chermansky CJ, Cruz F, Igawa Y, Lee KS, et al. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. 2023;75(4):554–674. https://doi.org/10.1124/pharmrev.121.000523.CrossRefPubMed

Kava MS, Blue DR Jr, Vimont RL, Clarke DE, Ford AP. Alpha1L-adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br J Pharmacol. 1998;123(7):1359–66. https://doi.org/10.1038/sj.bjp.0701748.CrossRefPubMed

10.

Robinson D, Abrams P, Cardozo L, Ellis-Jones J, Heath P, Wyllie M. The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):457–60. https://doi.org/10.1016/j.ejogrb.2011.07.030.CrossRefPubMed

11.

Wein AJ, Re. The efficacy and safety of PSD503 (Phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study: Editorial comment. J Urol. 2012;188(6):2301–2. https://doi.org/10.1016/j.juro.2012.08.157.CrossRefPubMed

12.

Balk EM, Rofeberg VN, Adam GP, Kimmel HJ, Trikalinos TA, Jeppson PC. Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in women: a systematic review and network Meta-analysis of clinical outcomes. Ann Intern Med. 2019;170(7):465–79. https://doi.org/10.7326/m18-3227.CrossRefPubMed

13.

Newman DK, Richter HE. 14 - Stress urinary incontinence and pelvic organ prolapse: Nonsurgical management. Urogynecology and Reconstructive Pelvic Surgery. Fifth. Elsevier Inc; 2022. p. 225–42.

14.

Morita T, Kihara K, Nagamatsu H, Oshima H, Kishimoto T. Effects of clenbuterol on rabbit vesicourethral muscle contractility. J Smooth Muscle Res. 1995;31(4):119–27. https://doi.org/10.1540/jsmr.31.119.CrossRefPubMed

15.

Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence. Urol Res. 2001;29(2):118–25. https://doi.org/10.1007/s002400100175.CrossRefPubMed

16.

Gilja I, Radej M, Kovacić M, Parazajder J. Conservative treatment of female stress incontinence with imipramine. J Urol. 1984;132(5):909–11. https://doi.org/10.1016/s0022-5347(17)49941-1.CrossRefPubMed

17.

Kornholt J, Sonne DP, Riis T, Sonne J, Klarskov N. Effect of imipramine on urethral opening pressure: a randomized, double-blind, placebo‐controlled crossover study in healthy women. Neurourol Urodyn. 2019;38(4):1076–80. https://doi.org/10.1002/nau.23955.CrossRefPubMed

18.

Klarskov N, Cerneus D, Sawyer W, Newgreen D, van Till O, Lose G. The effect of single oral doses of duloxetine, reboxetine, and midodrine on the urethral pressure in healthy female subjects, using urethral pressure reflectometry. Neurourol Urodyn. 2018;37(1):244–9. https://doi.org/10.1002/nau.23282.CrossRefPubMed

19.

Conlon K, Miner W, McCleary S, McMurray G. Identification of 5-HT(2 C) mediated mechanisms involved in urethral sphincter reflexes in a guinea-pig model of urethral function. BJU Int. 2012;110(2 Pt 2):E113–7. https://doi.org/10.1111/j.1464-410X.2011.10756.x.CrossRefPubMed

20.

Mariappan P, Ballantyne Z, N’Dow JM, Alhasso AA. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev. 2005;3Cd004742. https://doi.org/10.1002/14651858.CD004742.pub2.

21.

Neff D, Guise A, Guralnick ML, Langenstroer P, See WA, Jacobsohn KM, et al. Duloxetine for the treatment of post-prostatectomy stress urinary incontinence. Can Urol Assoc J. 2013;7(5–6):E260–2. https://doi.org/10.5489/cuaj.318.CrossRefPubMedPubMedCentral

22.

Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanás T. A systematic review of Efficacy, Safety, and tolerability of Duloxetine. Front Psychiatry. 2020;11:554899. https://doi.org/10.3389/fpsyt.2020.554899.CrossRefPubMedPubMedCentral

23.

Te West NID, Harris K, Jeffrey S, de Nie I, Parkin K, Roovers JP, et al. The effect of 12 weeks of estriol cream on stress urinary incontinence post-menopause: a prospective multinational observational study. Neurourol Urodyn. 2023;42(4):799–806. https://doi.org/10.1002/nau.25165.CrossRefPubMed

24.

Peters KM, Newman D, Belkoff L, Nandalur K, Johnston MA, Small S, PD05-09 ORAL ENOBOSARM SHOWS PROMISING ACTIVITY IN POST-MENOPAUSAL WOMEN WITH STRESS URINARY INCONTINENCE, et al. RESULTS OF A PHASE 2 STUDY. J Urol. 2018;199(4S):e148–e. https://doi.org/10.1016/j.juro.2018.02.417.CrossRef

25.

GTx Announces Top. -Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence. https://www.businesswire.com/news/home/20180921005082/en/GTx-Announces-Top-Line-Results-Placebo-Controlled-ASTRID-Trial. (2018). Accessed 20 Oct 2023.

26.

Kim MM, Kreydin EI. The Association of Serum Testosterone Levels and urinary incontinence in women. J Urol. 2018;199(2):522–7. https://doi.org/10.1016/j.juro.2017.08.093.CrossRefPubMed

27.

Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence. https://classic.clinicaltrials.gov/ct2/show/NCT03116087. (2018). Accessed 20 Oct 2023.

28.

Gažová A, Valášková S, Žufková V, Castejon AM, Kyselovič J. Clinical study of effectiveness and safety of CELcomplex(®) containing Cucurbita Pepo seed extract and Flax and Casuarina on stress urinary incontinence in women. J Tradit Complement Med. 2019;9(2):138–42. https://doi.org/10.1016/j.jtcme.2017.10.005.CrossRefPubMed

29.

Mizutani H, Sakakibara F, Komuro M, Sasaki E. TAS-303, a novel selective norepinephrine reuptake inhibitor that increases urethral pressure in rats, indicating its potential as a therapeutic agent for stress urinary incontinences. J Pharmacol Exp Ther. 2018;366(2):322–31. https://doi.org/10.1124/jpet.118.248039.CrossRefPubMed

30.

Yono M, Irie S, Gotoh M. TAS-303 effects on urethral sphincter function in women with stress urinary incontinence: phase I study. Int Urogynecol J. 2021;32(3):673–80. https://doi.org/10.1007/s00192-020-04470-7.CrossRefPubMed

31.

Takahashi S, Kato K, Yokoyama O, Takei M, Gotoh M. 274 a phase 2, randomized, placebo-controlled, double-blind study of TAS-303 in female patients with stress urinary incontinence. Continence. 2022;2:100340. https://doi.org/10.1016/j.cont.2022.100340.CrossRef

32.

Akita Y, Sumino Y, Mori K, Nomura T, Sato F, Mimata H. Myostatin inhibits proliferation of human urethral rhabdosphincter satellite cells. Int J Urol. 2013;20(5):522–9. https://doi.org/10.1111/j.1442-2042.2012.03186.x.CrossRefPubMed

33.

Yang J, Balog B, Deng K, Hanzlicek B, Rietsch A, Kuang M, et al. Therapeutic potential of muscle growth promoters in a stress urinary incontinence model. Am J Physiol Ren Physiol. 2020;319(3):F436-46. https://doi.org/10.1152/AJPRENAL.00122.2020.CrossRef

34.

Naumann G, Aigmüller T, Bader W, Bauer R, Beilecke K, Betschart Meier C, et al. Diagnosis and therapy of female urinary incontinence. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry 015/091, January 2022): part 1 with recommendations on Diagnostics and Conservative and Medical Treatment. Geburtshilfe Frauenheilkd. 2023;83(4):377–409. https://doi.org/10.1055/a-1967-1726.CrossRefPubMedPubMedCentral

35.

Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer Risk Associated with Lorcaserin — the FDA’s review of the CAMELLIA-TIMI 61 trial. N Engl J Med. 2020;383(11):1000–2. https://doi.org/10.1056/NEJMp2003873.CrossRefPubMed

36.

Ishigami T, Ueshima K, Ukai M, Asai N, Takamatsu H, Yokono M, et al. Effect of ASP2205 fumarate, a novel 5-HT(2 C) receptor agonist, on urethral closure function in rats. J Pharmacol Sci. 2019;139(4):333–9. https://doi.org/10.1016/j.jphs.2019.02.004.CrossRefPubMed

37.

Kamo I, Nagata H, O’Connell G, Kato T, Imanishi A, Kuno M, et al. Increasing effects of selective 5-Hydroxytryptamine type 2 C receptor stimulation on Evoked Momentary Urethral Closure in female rats and humans. J Pharmacol Exp Ther. 2021;378(2):60–8. https://doi.org/10.1124/jpet.121.000573.CrossRefPubMed

38.

Takeda and Frazier Healthcare Partners Launch Outpost Medicine to Develop New Therapeutics in Urology and Gynecology. https://www.fiercebiotech.com/biotech/takeda-and-frazier-healthcare-partners-launch-outpost-medicine-to-develop-new-therapeutics. (2016). Accessed 20 Oct 2023.

39.

Kobashi KC, Vasavada S, Bloschichak A, Hermanson L, Kaczmarek J, Kim SK, et al. Updates to Surgical Treatment of female stress urinary incontinence (SUI): AUA/SUFU Guideline (2023). J Urol. 2023;209(6):1091–8. https://doi.org/10.1097/JU.0000000000003435.CrossRefPubMed

40.

Nambiar AK, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, et al. European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49–59. https://doi.org/10.1016/j.eururo.2022.01.045.CrossRefPubMed

41.

Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10(10):Cd001405. https://doi.org/10.1002/14651858.CD001405.pub3.CrossRefPubMed

42.

Sweeney DD, Chancellor MB. Treatment of stress urinary incontinence with duloxetine hydrochloride. Rev Urol. 2005;7(2):81–6.PubMedPubMedCentral

43.

Alhasso A, Glazener CMA, Pickard R, N’Dow JMO. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev. 2005. https://doi.org/10.1002/14651858.CD001842.pub2.CrossRefPubMedPubMedCentral

44.

Mangır N, Uçar M, Gülpınar Ö, Özkürkçügil Cn, Demirkesen O, Tarcan T. Duloxetine in the treatment of women with urinary incontinence: a systematic review and Meta-analysis of Efficacy Data from Randomized Controlled clinical trials. J Urol Surg. 2023;10(1):1–8. https://doi.org/10.4274/jus.galenos.2022.2022.0027.CrossRef

45.

Thyssen HH, Clevin L, Olesen S, Lose G. Urinary incontinence in elite female athletes and dancers. Int Urogynecol J Pelvic Floor Dysfunct. 2002;13(1):15–7. https://doi.org/10.1007/s001920200003.CrossRefPubMed

46.

Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ. 2017;189(5):E194–203. https://doi.org/10.1503/cmaj.151104.CrossRefPubMedPubMedCentral

47.

Ganz M, Alessandro C, Jacobs M, Miller D, Diah J, Winer A, et al. The role of body Mass Index and Waist circumference in gender-specific risk factors for stress urinary incontinence: a cross-sectional study. Cureus. 2023;15(5):e38917. https://doi.org/10.7759/cureus.38917.CrossRefPubMedPubMedCentral

Title: Pharmacotherapy in Stress Urinary Incontinence; A Literature Review
Authors: Seyed Sajjad Tabei
Wesley Baas
Ayman Mahdy
Publication date: 10-05-2024
Publisher: Springer US
Keywords: Stress Incontinence
Duloxetine
Urinary Incontinence
Urinary Incontinence
Published in: Current Urology Reports
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-024-01205-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacotherapy in Stress Urinary Incontinence; A Literature Review

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content